Neoadjuvant therapy for pancreatic cancer: an ongoing debate.
作者信息
Russo Suzanne, Saif M Wasif
机构信息
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Tufts University School of Medicine, 800 Washington Street, Suite 7099, 7-S, Boston, MA 02111, USA.
出版信息
Therap Adv Gastroenterol. 2016 Jul;9(4):429-36. doi: 10.1177/1756283X16646524. Epub 2016 May 10.
Abstract
摘要
相似文献
1
Neoadjuvant therapy for pancreatic cancer: an ongoing debate.胰腺癌的新辅助治疗：一场持续的争论。
Therap Adv Gastroenterol. 2016 Jul;9(4):429-36. doi: 10.1177/1756283X16646524. Epub 2016 May 10.
2
Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.非转移性胰腺导管腺癌的新辅助治疗
Semin Oncol. 2015 Feb;42(1):86-97. doi: 10.1053/j.seminoncol.2014.12.008. Epub 2014 Dec 9.
3
Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer.新辅助治疗对可切除胰腺癌至关重要。
Curr Med Chem. 2019;26(40):7196-7211. doi: 10.2174/0929867325666180413101722.
4
A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.新辅助治疗策略在非转移性胰腺癌治疗中的应用。
Cancer J. 2012 Nov-Dec;18(6):602-8. doi: 10.1097/PPO.0b013e318279aade.
5
Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.可切除胰腺癌的辅助和新辅助治疗：随机对照试验的系统评价
Med Oncol. 2016 Mar;33(3):28. doi: 10.1007/s12032-016-0742-z. Epub 2016 Feb 17.
6
[Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].[新辅助化疗对可切除胰腺癌的疗效]
Gan To Kagaku Ryoho. 2013 Nov;40(12):1632-6.
7
Neoadjuvant therapy in pancreatic cancer: review article.
JOP. 2015 Mar 20;16(2):110-4. doi: 10.6092/1590-8577/2940.
8
[Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].[可切除胰腺癌新辅助治疗的进展与争议]
Zhonghua Wai Ke Za Zhi. 2020 Jul 1;58(7):486-489. doi: 10.3760/cma.j.cn112139-20200422-00318.
9
Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment.胰腺癌的转化手术——新辅助治疗的影响
Front Oncol. 2020 Jan 14;9:1501. doi: 10.3389/fonc.2019.01501. eCollection 2019.
10
Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.与直接手术相比，新辅助治疗可切除和边界可切除胰腺癌后的长期结局：一项意向性分析比较研究的荟萃分析。
Surg Today. 2019 Apr;49(4):295-299. doi: 10.1007/s00595-019-01786-w. Epub 2019 Mar 15.
引用本文的文献
1
Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.四分级病理性肿瘤退缩分级系统预测新辅助化疗后接受手术切除局部晚期胰腺癌患者的临床结局。
Gut Liver. 2022 Jan 15;16(1):129-137. doi: 10.5009/gnl20312.
2
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.可切除及边界可切除胰腺腺癌新辅助放化疗联合或不联合全身化疗的疗效
Front Oncol. 2020 Sep 16;10:1461. doi: 10.3389/fonc.2020.01461. eCollection 2020.
3
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.比较新辅助化疗方案（吉西他滨与 FOLFIRINOX）对交界可切除胰腺癌的临床疗效。
Gut Liver. 2021 May 15;15(3):466-475. doi: 10.5009/gnl20070.
4
Completion of adjuvant therapy in patients with resected pancreatic cancer.辅助治疗在胰腺癌患者中的完成情况。
HPB (Oxford). 2020 Feb;22(2):241-248. doi: 10.1016/j.hpb.2019.07.008. Epub 2019 Sep 25.
5
Recent advances in radiation therapy of pancreatic cancer.胰腺癌放射治疗的最新进展
F1000Res. 2018 Dec 13;7. doi: 10.12688/f1000research.16272.1. eCollection 2018.
6
High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study.切除的胰腺癌患者对指南建议的依从性高，但辅助化疗完成率低：一项队列研究。
Ann Med Surg (Lond). 2018 Jun 27;32:32-37. doi: 10.1016/j.amsu.2018.06.004. eCollection 2018 Aug.
本文引用的文献
1
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.新辅助放化疗后对可切除边缘的胰腺癌进行切除并不取决于肿瘤与血管关系的影像学表现改善。
J Radiat Oncol. 2013 Dec;2(4):413-425. doi: 10.1007/s13566-013-0115-6. Epub 2013 Sep 22.
2
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.诱导化疗联合新辅助立体定向体部放疗治疗可切除边缘和局部晚期胰腺腺癌的长期疗效
Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3.
3
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.立体定向体部放射治疗在胰腺癌治疗中的作用：单机构经验
Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.
4
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.评估吉西他滨与立体定向体部放疗用于局部晚期不可切除胰腺腺癌患者的2期多机构试验。
Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.
5
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.吉西他滨/顺铂新辅助放化疗联合手术与直接手术治疗可切除胰腺癌的比较：首个前瞻性随机II期试验结果
Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.
6
Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).序贯新辅助放化疗（CRT）后行根治性手术与单纯一期手术治疗可切除、无转移的胰腺腺癌：NEOPA-一项随机多中心III期研究（NCT01900327、DRKS00003893、ISRCTN82191749）
BMC Cancer. 2014 Jun 7;14:411. doi: 10.1186/1471-2407-14-411.
7
Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.老年胰腺腺癌患者的治疗轨迹和多模式治疗的应用。
Surgery. 2014 Aug;156(2):280-9. doi: 10.1016/j.surg.2014.03.001. Epub 2014 Mar 14.
8
Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.高度优化的靶向人端粒酶逆转录酶的 DNA 疫苗刺激强烈的抗肿瘤免疫。
Cancer Immunol Res. 2013 Sep;1(3):179-189. doi: 10.1158/2326-6066.CIR-13-0001. Epub 2013 Jul 17.
9
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.一项在晚期胰腺导管腺癌患者中联合吉西他滨应用激动型 CD40 单克隆抗体（CP-870,893）的 I 期研究。
Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.
10
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.诱导固定剂量率吉西他滨和贝伐珠单抗联合 30 Gy 放疗作为潜在可切除胰腺癌的术前治疗的 II 期研究。
Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1.
Zotero 插件